Bevacizumab (Avastin ®), which
targets vascular endothelial growth factor (VEGF), is FDA - approved for the treatment of ovarian cancer.
Other progress against the wet form of the disease has come through the use of drugs that
target vascular endothelial growth factor.
Not exact matches
Bevacizumab, a monoclonal antibody, is an angiogenesis inhibitor that
targets a chemical signal,
vascular endothelial growth factor A (VEGF - A).
The drug, marketed as Lucentis,
targets a molecule called
vascular endothelial growth factor (VEGF), a key player in the
growth of blood vessels.
Adults with advanced renal cell carcinoma after
targeted therapy against
vascular endothelial growth factor (VEGF)
[6] Another natural isoflavinoid, 4 - O - methyl alpinumisoflavone, isolated from the tropical rainforest tree, Lonchocarpus glabrescens, could inhibit HIF - 1 activation and hypoxic induction of HIF - 1
target genes (CDKN1A, GLUT - 1, and
vascular endothelial growth factor (VEGF)-RRB-.
The use of
targeting antibodies against
vascular endothelial growth factor (VEGF), a protein that promotes tumor
growth and spread, plus chemotherapy has prolonged disease free survival in several different tumor types in man.